Pharmacogenetics of thiopurines

Abstract

Polychemotherapeutic protocols for the treatment of pediatric acute lymphoblastic leukemia (ALL) always include thiopurines. Specific approaches vary in terms of drugs, dosages and combinations. Such therapeutic schemes, including risk-adapted intensity, have been extremely successful for children with ALL who have reached an outstanding 5-year survival of greater than 90% in developed countries. Innovative drugs such as the proteasome inhibitor bortezomib and the bi-specific T cell engager blinatumomab are available to further improve therapeutic outcomes. Nevertheless, daily oral thiopurines remain the backbone maintenance or continuation therapy. Pharmacogenetics allows the personalization of thiopurine therapy in pediatric ALL and clinical guidelines to tailor therapy on the basis of genetic variants in TPMT and NUDT15 genes are already available. Other genes of interest, such as ITPA and PACSIN2, have been implicated in interindividual variability in thiopurines efficacy and adverse effects and need additional research to be implemented in clinical protocols. In this review we will discuss current literature and clinical guidelines available to implement pharmacogenetics for tailoring therapy with thiopurines in pediatric ALL.

Keywords

Thiopurines / acute lymphoblastic leukemia / therapy personalization / thiopurine methyltransferase / NUDT15 / PACSIN2 / inosine triphosphate pyrophosphatase / pharmacogenetics clinical implementation

References

[1] Adamson PC,Balis FM.The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia..Leuk Res1994;18:805-10

[2] Lucafò M,Selvestrel D,Pugnetti L.Pharmacogenetics of treatments for inflammatory bowel disease..Expert Opin Drug Metab Toxicol2018;14:1209-23

[3] Cara CJ,Sans M,Guerrero-Esteo M.Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice..Med Sci Monit2004;10:RA247-54

[4] Berends SE,Löwenberg M,Mathôt RAA.Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis..Clin Pharmacokinet2019;58:15-37 PMCID:PMC6326086

[5] Krenitsky TA,Elion GB.Human hypoxanthine phosphoribosyltransferase. I. Purification, properties, and specificity..J Biol Chem1969;244:1263-70

[6] Adam de Beaumais T,Medard Y,Zhang D.Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy..Br J Clin Pharmacol2011;71:575-84 PMCID:PMC3080646

[7] Nguyen CM,Ma JD.Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk..PLoS Curr2011;3:RRN1236 PMCID:PMC3094768

[8] Dubinsky MC,Yang HY,Sinnett D.Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease..Gastroenterology2000;118:705-13

[9] Ben-Horin S,Chowers Y,Ungar B.Pharmacokinetics and immune reconstitution following discontinuation of thiopurine analogues: implications for drug withdrawal strategies..J Crohns Colitis2018;12:1410-7

[10] Derijks LJ,Engels LG,Bus PJ.Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy..Ther Drug Monit2004;26:311-8

[11] Lancaster DL,Lennard L.Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia..Cancer Chemother Pharmacol2002;50:33-6

[12] Cuffari C,Latour S.Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn’s disease patients on maintenance 6-mercaptopurine therapy..Can J Physiol Pharmacol1996;74:580-5

[13] Stocco G,Verzegnassi F,Rabusin M.Pharmacogenomic approaches for tailored anti-leukemic therapy in children..Curr Med Chem2013;20:2237-53

[14] Franca R,Sorio C,Montecchini O.Targeting kinase-activating genetic lesions to improve therapy of pediatric acute lymphoblastic leukemia..Curr Med Chem2018;25:2811-25

[15] Ling Y,Zhang Z.Protein kinase inhibitors for acute leukemia..Biomark Res2018;6:8 PMCID:PMC5809833

[16] Avallone EV,Cassieri C,Paoluzi P.Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects..Eur Rev Med Pharmacol Sci2014;18:165-70

[17] Ledder O,Day AS.Thiopurine-induced pancreatitis in inflammatory bowel diseases..Expert Rev Gastroenterol Hepatol2015;9:399-403

[18] Citterio-Quentin A,Perret T,Ryan A.Red Blood cell IMPDH activity in adults and children with or without azathioprine: relationship between thiopurine metabolites, ITPA and TPMT activities..Basic Clin Pharmacol Toxicol2018;

[19] Urbančič D,Šmid A,Gobec S.Methylation of selenocysteine catalysed by thiopurine S-methyltransferase..Biochim Biophys Acta Gen Subj2019;1863:182-90

[20] Schwarz G, Csaszar J, Schaeffeler E, Schwab, M. Diagnostic in vitro method, 2013 [Application number: US20160160264A1]. Available from: https://patents.google.com/patent/US20160160264A1/en. [Last accessed on 15 Apr 2019].

[21] Collie-Duguid ES,Powrie RH,Collier DA.The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations..Pharmacogenetics1999;9:37-42

[22] Schaeffeler E,Brockmeier D,Moerike K.Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants..Pharmacogenetics2004;14:407-17

[23] Liu C,Pei D,Smith C.Genomewide approach validates thiopurine methyltransferase activity is a monogenic pharmacogenomic trait..Clin Pharmacol Ther2017;101:373-81 PMCID:PMC5309133

[24] Tiede I,Strand S,Dvorsky R.CD28-dependent Rac-1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes..J Clin Invest2003;111:1133-45 PMCID:PMC152932

[25] Yates CR,Loennechen T,Tai HL.Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance..Ann Intern Med1997;126:608-14

[26] Hindorf U.Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function..J Crohns Colitis2012;6:655-9

[27] Chadli Z,Hannachi I,Ben Fredj N.Distribution of genetic polymorphisms of genes implicated in thiopurine drugs metabolism..Ther Drug Monit2018;40:655-9

[28] Saiz-Rodríguez M,Belmonte C,Martínez-Ingelmo C.Influence of thiopurine S-methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers..Basic Clin Pharmacol Toxicol2019;124:449-55

[29] Oliveira E,Alves S,Prata MJ.Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique..Eur J Clin Pharmacol2007;63:703-6

[30] Tai HL,Schuetz EG,Evans WE.Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity..Proc Natl Acad Sci U S A.1997;94:6444-9 PMCID:PMC21069

[31] Wang L,Toft D.Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation..Pharmacogenetics2003;13:555-64

[32] Wang L,McLaughlin RW,Ramirez-Alvarado M.Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation..Proc Natl Acad Sci U S A.2005;102:9394-9 PMCID:PMC1153717

[33] Coenen MJ,van Marrewijk CJ,Vermeulen SH.Identification of patients with variants in tpmt and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease..Gastroenterology2015;149:907-17.e7

[34] Hartford C,Schwab M,Rehg JE.Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics..Cancer Res2007;67:4965-72

[35] Relling MV,Sandborn WJ,Pui CH.Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing..Clin Pharmacol Ther2011;89:387-91 PMCID:PMC3098761

[36] Relling MV,Whirl-Carrillo M,Pui CH.Clinical pharmacogenetics implementation consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update..Clin Pharmacol Ther2018;

[37] Meijer B,van Moorsel SAW,Bouma G.6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients..J Gastroenterol Hepatol2017;32:1183-90

[38] Yang SK,Baek J,Zhao W.A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia..Nat Genet2014;46:1017-20 PMCID:PMC4999337

[39] Yang JJ,Scott SA,Schwab M.Pharmacogene variation consortium gene introduction: NUDT15..Clin Pharmacol Ther2018;

[40] Kakuta Y,Shimosegawa T.Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping..J Gastroenterol2018;53:172-80 PMCID:PMC5846876

[41] Yang JJ,Yang W,Hageman L.Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia..J Clin Oncol2015;33:1235-42 PMCID:PMC4375304

[42] Moriyama T,Perez-Andreu V,Klussmann FA.NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity..Nat Genet2016;48:367-73 PMCID:PMC5029084

[43] Yin D,Zhang J,Liao F.Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose..Oncotarget2017;8:13575-85 PMCID:PMC5355121

[44] Cargnin S,Canonico PL.Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis..Pharmacol Res2018;135:102-11

[45] Lek M,Minikel EV,Banks E.Analysis of protein-coding genetic variation in 60,706 humans..Nature2016;536:285-91 PMCID:PMC5018207

[46] Walker G, Harrison J, Voskuil M, Heap G, Heerasing N. NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations. 2018. Available from: https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2018/item/op035-nudt15-variants-contribute-to-thiopurine-induced-myelosuppression-in-european-populations.html. [Last accessed on 15 Apr 2019]

[47] Moriyama T,Lin TN,Toyoda H.The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia..Pharmacogenet Genomics2017;27:236-9 PMCID:PMC5510236

[48] Lin S,Ying K,Gu S.Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene..J Biol Chem2001;276:18695-701

[49] Burgis NE.A disease spectrum for ITPA variation: advances in biochemical and clinical research..J Biomed Sci2016;23:73 PMCID:PMC5075207

[50] Sumi S,Arenas M,Shobowale-Bakre M.Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency..Hum Genet2002;111:360-7

[51] Behmanesh M,Abolhassani N,Oka S.ITPase-deficient mice show growth retardation and die before weaning..Cell Death Differ2009;16:1315-22

[52] Vanderheiden BS.Possible implication of an inosinetriphosphate metabolic error and glutamic acid decarboxylase in paranoid schizophrenia..Biochem Med1979;21:22-32

[53] Nakauchi A,Mahasirimongkol S,Yuliwulandari R.Identification of ITPA on chromosome 20 as a susceptibility gene for young-onset tuberculosis..Hum Genome Var2016;3:15067 PMCID:PMC4760120

[54] Mollaahmadi F,Salman Yazdi R.The rs1127354 polymorphism in itpa is associated with susceptibility to infertility..Cell J2018;20:73-7 PMCID:PMC5759682

[55] Stenmark P,Flodin S,Landry R.Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T..J Biol Chem2007;282:3182-7

[56] Marsh S,Ahluwalia R.Distribution of ITPA P32T alleles in multiple world populations..J Hum Genet2004;49:579-81

[57] Fellay J,Ge D,Urban TJ.ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C..Nature2010;464:405-8

[58] Coelho AV,Zandonà L,Decorti G.Role of inosine triphosphate pyrophosphatase gene variant on fever incidence during zidovudine antiretroviral therapy..Genet Mol Res2017;16:

[59] Stocco G,Crews KR,French D.Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia..Clin Pharmacol Ther2009;85:164-72 PMCID:PMC2762405

[60] Kim H,Kim HJ,Kim NH.Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism..PLoS One2012;7:e45558 PMCID:PMC3454425

[61] Wan Rosalina WR,Mohamad N,Yusoff R.Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine..J Clin Pharm Ther2012;37:237-41

[62] Franca R,Bertorello N,Conter V.Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol..Pharmacogenomics J2017;17:4-10

[63] Modregger J,Witter B,Plomann M.All three PACSIN isoforms bind to endocytic proteins and inhibit endocytosis..J Cell Sci2000;113:4511-21

[64] Frost A,De Camilli P.The BAR domain superfamily: membrane-molding macromolecules..Cell2009;137:191-6 PMCID:PMC4832598

[65] Peter BJ,Mills IG,Butler PJ.BAR domains as sensors of membrane curvature: the amphiphysin BAR structure..Science2004;303:495-9

[66] Senju Y,Shah C,Itoh Y.Phosphorylation of PACSIN2 by protein kinase C triggers the removal of caveolae from the plasma membrane..J Cell Sci2015;128:2766-80

[67] de Kreuk BJ,Geerts D.The F-BAR protein PACSIN2 regulates epidermal growth factor receptor internalization..J Biol Chem2012;287:43438-53 PMCID:PMC3527931

[68] Hansen CG,Nichols BJ.Pacsin 2 is recruited to caveolae and functions in caveolar biogenesis..J Cell Sci2011;124:2777-85

[69] Ritter B,Paulsson M.PACSIN 2, a novel member of the PACSIN family of cytoplasmic adapter proteins..FEBS Lett1999;454:356-62

[70] Stocco G,Crews KR,Decorti G.PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity..Hum Mol Genet2012;21:4793-804 PMCID:PMC3471396

[71] Smid A,Jazbec J.PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy..Sci Rep2016;6:30244 PMCID:PMC4958958

[72] Lam BD.The Rac-1 hypervariable region in targeting and signaling: a tail of many stories..Small GTPases2013;4:78-89 PMCID:PMC3747260

[73] Seinen ML,de Boer NK,van Bezu J.Rac-1 as a potential pharmacodynamic biomarker for thiopurine therapy in inflammatory bowel disease..Ther Drug Monit2016;38:621-7

[74] Shin JY,Umutesi HG,Simecka J.Thiopurine prodrugs mediate immunosuppressive effects by interfering with Rac-1 protein function..J Biol Chem2016;291:13699-714 PMCID:PMC4919453

[75] Sugihara K,Nakamura K,Hashimoto R.Rac-1 is required for the formation of three germ layers during gastrulation..Oncogene1998;17:3427-33

[76] Poppe D,Fritz G,Bartsch B.Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins..J Immunol2006;176:640-51 PMCID:PMC1965586

[77] Muise AM,Xu W,Guo CH.Single nucleotide polymorphisms that increase expression of the guanosine triphosphatase Rac-1 are associated with ulcerative colitis..Gastroenterology2011;141:633-41 PMCID:PMC3152589

[78] Lev-Tzion R,Beeri R,Mevorach R.Rac-1 polymorphisms and thiopurine efficacy in children with inflammatory bowel disease..J Pediatr Gastroenterol Nutr2015;61:404-7

[79] Koifman E,Mazor Y,Waterman M.Thiopurine effectiveness in patients with Crohn’s disease: a study of genetic and clinical predictive factors..Inflamm Bowel Dis2013;19:1639-44

[80] Fisel P,Schwab M.DNA methylation of ADME genes..Clin Pharmacol Ther2016;99:512-27

[81] De Abreu R,Stet E,Van den Heuvel L.Thiopurine induced disturbance of DNA methylation in human malignant cells..Adv Enzyme Regul1995;35:251-63

[82] Lambooy LH,van den Heuvel LP,De Abreu RA.Inhibition of DNA methylation in malignant MOLT F4 lymphoblasts by 6-mercaptopurine..Clin Chem1998;44:556-9

[83] Hogarth LA,Teodoridis JM,Anderson H.The effect of thiopurine drugs on DNA methylation in relation to TPMT expression..Biochem Pharmacol2008;76:1024-35

[84] Lisanti S,Tomaszewski B,Jacobs G.Comparison of methods for quantification of global DNA methylation in human cells and tissues..PLoS One2013;8:e79044 PMCID:PMC3832524

[85] Taki K,Ise R,Yoshida T.Microarray analysis of 6-mercaptopurine-induced-toxicity-related genes and microRNAs in the rat placenta..J Toxicol Sci2013;38:159-67

[86] Burgess KS,Benson EA,Gaedigk A.Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver..Clin Pharmacol Ther2015;98:205-15 PMCID:PMC4512918

[87] Stocco G,Arrigo S,Aloi M.Multicentric case-control study on azathioprine dose and pharmacokinetics in early-onset pediatric inflammatory bowel disease..Inflamm Bowel Dis2017;23:628-34

[88] Whirl-Carrillo M,Hebert JM,Sangkuhl K.Pharmacogenomics knowledge for personalized medicine..Clin Pharmacol Ther2012;92:414-7 PMCID:PMC3660037

[89] Kornbluth A,Gastroenterology PPCotACo.Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee..Am J Gastroenterol2010;105:501-23

[90] Relling MV.Pharmacogenomics in the clinic..Nature2015;526:343-50 PMCID:PMC4711261

[91] Stocco G,Barabino A,Lionetti P.TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease..Dig Liver Dis2005;37:940-5

[92] von Ahsen N,Oellerich M.Rapid, long-range molecular haplotyping of thiopurine S-methyltransferase (TPMT) *3A, *3B, and *3C..Clin Chem2004;50:1528-34